Microdosing tirzepatide means using doses below the escalation schedule the trials used. The tolerability logic is reasonable and clinicians use it deliberately. The evidence base for it, as a defined protocol with defined outcomes, does not exist. Both of those things are true at once.
GLP-1 Therapy
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
Microdosing, in this context, means taking tirzepatide at doses below the standard trial escalation, or holding at a low dose indefinitely rather than climbing to a target. In practice that usually means staying at or under 2.5mg weekly, sometimes splitting a weekly dose across smaller more frequent injections, sometimes stretching intervals out to every ten or fourteen days.
It is worth separating two situations that get blurred. The first is a clinician deliberately starting low, escalating slowly, and holding at whatever dose produces an acceptable balance of effect and side effects for that patient. That is ordinary titration and it is how the drug is supposed to be used. The second is a protocol marketed as its own therapy, with claimed benefits like fewer side effects, preserved muscle, or lower cost, promoted with dosing charts that circulate on forums and social platforms.
The first is medicine. The second is a claim, and claims need evidence. This article is mostly about how little evidence exists for the second.
SURMOUNT-1 randomized 2,539 adults with obesity, or overweight with a weight-related complication and without diabetes, to weekly tirzepatide at 5mg, 10mg, or 15mg, or placebo, for 72 weeks, all alongside lifestyle counselling.1 Mean weight change at 72 weeks ran from roughly 15 percent at 5mg to roughly 21 percent at 15mg.
Read the dose arms carefully. The lowest studied maintenance dose was 5mg weekly, reached through a standard escalation from 2.5mg. There is no 1mg arm. There is no every-other-week arm. There is no split-dose arm. Anyone quoting SURMOUNT-1 percentages while recommending a fraction of the studied dose is attaching trial outcomes to a regimen the trial did not test.
The randomized ingestive-behavior trial that measured how much people actually ate at a laboratory test meal used clinical doses as well.2 The finding that participants consumed on the order of 500 fewer calories than placebo is a real human result at a real dose. It is not a result at a tenth of that dose, and appetite effects of incretin drugs are consistently dose-dependent.
This does not prove low doses do nothing. Dose-response curves are curves, not switches, and it is entirely plausible that a low dose produces a partial effect. Plausible is the correct word. It has not been measured.
The dosing charts you find online, the ones with weekly milligram ladders, unit conversions, and confident week-by-week schedules, are not extracted from a publication. They are community documents, assembled from anecdote, vendor guidance, and each other, then reformatted until they look like clinical protocols.
There are two specific risks in following one. The first is dosing arithmetic. Tirzepatide is dosed in milligrams, but many people are drawing from a reconstituted vial and measuring in insulin syringe units, which requires a conversion that depends on the concentration of that specific vial. Errors here are order-of-magnitude errors, and they run in both directions.
The second is the absence of anyone watching. Escalation decisions, side-effect management, contraindication screening, and monitoring for the uncommon but serious problems associated with this class are not tasks a chart performs. They are the reason a prescriber exists in the pathway.
Having said all of that, the impulse behind low and slow dosing is not irrational, and dismissing it entirely would be its own form of dishonesty.
Gastrointestinal adverse effects in SURMOUNT-1 were predominantly mild to moderate, clustered during dose escalation, and were the leading cause of discontinuation.1 That is a straightforward argument for escalating no faster than a person tolerates. A patient who stays on 2.5mg comfortably for three months is getting more cumulative therapy than a patient who reaches 10mg, feels terrible, and quits in week six.
There is also individual variation in response. Some people show substantial appetite change at the starting dose and have no clinical reason to climb further. Holding at an effective low dose is a reasonable clinical decision when a clinician is measuring the response and adjusting deliberately.
The distinction that matters is authorship. Clinician-guided gradual dosing is titration with a feedback loop. A protocol downloaded from a forum has no feedback loop, no screening, and no accountability, and it borrows credibility from trials that studied something else.
One study frequently cited in low-dose discussions found that tirzepatide suppressed palatable food intake by selectively reducing preference for fat in rodents.3 It is an interesting result: the drug did not simply reduce total intake, it shifted what the animals chose to eat.
Label it accurately. This is animal data. Rodent food-preference paradigms are useful for generating hypotheses about central appetite circuits, and they are a poor basis for human dosing decisions. Species differences in taste, reward, and metabolism are substantial, and food preference in a cage with two feeders is not food choice in a human life.
It is legitimate to find this suggestive. It is not legitimate to present it as evidence that a particular dose changes what a person craves. That claim requires a human trial measuring human food choice, and it has not been run at microdose levels.
If you are considering a lower-dose approach, the useful frame is that you are choosing a tolerability strategy, not a distinct therapy with its own evidence base. That framing keeps expectations calibrated: you may get a partial effect, you may need to escalate later, and the published percentages do not apply to you.
Compounded tirzepatide is prepared for an individual patient by a state-licensed US compounding pharmacy on a physician's prescription and is not an FDA-approved product. Using it at a nonstandard dose is a clinical decision that should be made with the prescriber who is monitoring you, and documented, so that if the response is inadequate the next step is a plan rather than a guess.
The one thing we will not do is publish a microdosing chart. There is no study to base one on, and inventing a schedule that looks authoritative would be exactly the behavior this article is arguing against.
Gradual dosing is a defensible clinical tactic. A microdosing protocol with promised outcomes is a marketing claim. The distance between those two sentences is the entire subject of this article.
Astra Editorial
No. Published weight and metabolic outcomes come from trials using the standard escalation to 5mg, 10mg, or 15mg weekly. No randomized trial has tested a defined microdose protocol.
Gastrointestinal side effects in the pivotal trial were dose-related and concentrated during escalation, so slower escalation is a reasonable tolerability strategy. That is different from a guarantee, and it is not the same as a tested protocol.
They are not derived from any study. They are community documents. Unit-to-milligram conversion errors and unsupervised escalation are the two most common ways people get hurt following them.
Compounded tirzepatide — online evaluation. Only charged if prescribed. If a gradual dosing approach is right for you, that is a decision to make with a licensed physician who can screen, titrate, and monitor rather than with a chart from a forum.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.